Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial

NCT07389980 is registered in ClinicalTrials.gov with Yeungnam University College of Medicine as lead sponsor.

NCT NCT07389980
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07389980 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial
Lead sponsor
Yeungnam University College of Medicine
Phase
Phase 3
Overall status
Recruiting
Start date
December 24, 2026
Completion date
December 31, 2028
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

polypoidal choroidal vasculopathy, polypoidal choroidal vasculopathy (pcv)